Earnings Summary

Chemomab Therapeutics Ltd’s net profit jumped 58.24% since last year same period to $-3.45Mn in the Q4 2023. On a quarterly growth basis, Chemomab Therapeutics Ltd has generated 15.09% jump in its net profits since last 3-months.

Chemomab Therapeutics Ltd’s earning per share (EPS) estimates for the current quarter stand at -0.03 - a -50% fall from last quarter’s estimates.

Chemomab Therapeutics Ltd’s earning per share (EPS) estimates for the current year stand at -0.03.

Chemomab Therapeutics Ltd’s earning per share (EPS) fell -563.5% since last year same period to -0.27 in the Q4 2023. This indicates that the Chemomab Therapeutics Ltd has generated -563.5% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Chemomab Therapeutics Ltd’s return on assets (ROA) stands at -0.49.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Chemomab Therapeutics Ltd’s return on equity (ROE) stands at -0.91.